中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
17期
2653-2656
,共4页
依折麦布%阿托伐他汀%老年人%冠心病%血脂
依摺麥佈%阿託伐他汀%老年人%冠心病%血脂
의절맥포%아탁벌타정%노년인%관심병%혈지
Ezetimibe%Atorvastatin%Elderly patient%Coronary heart disease%Serum lipid
目的:探讨胆固醇吸收抑制剂与高剂量阿托伐他汀联用于血脂控制不佳老年冠心病患者的临床效果及安全性差异。方法选取血脂控制不佳老年冠心病患者共240例,以随机抽样方法分为三组,即A组(80例)、B组(80例)即C组(80例),分别采用阿托伐他汀常规剂量,阿托伐他汀高剂量及阿托伐他汀高剂量+胆固醇吸收抑制依折麦布治疗,比较三组总胆固醇(TC )、低密度脂蛋白胆固醇(LDL-C )达标率,治疗前后血脂指标及不良反应发生率等。结果 A、B 及 C 组 TC 达标率分别为40.00%(32/80)、62.50%(50/80)、96.25%(77/80);A、B 及 C 组 LDL-C 达标率分别为51.25%(41/80)、81.25%(65/80)、98.75%(79/80);C组TC和LDL-C达标率显著优于A、B组,差异有统计学意义(χ2=58.28、27.83、48.13、13.61,均P<0.05);A组治疗后TC、TG、LDL-C及HDL-C分别为(5.35±1.26)mmol/L、(2.10±0.83)mmol/L、(2.85±0.93)mmol/L、(1.23±0.67)mmol/L;B 组治疗后 TC、TG、LDL-C 及 HDL-C 分别为(4.97±1.02)mmol/L,(2.05±0.81)mmol/L,(2.47±0.86)mmol/L,(1.20±0.65)mmol/L;C组治疗后TC、TG、LDL-C及HDL-C分别为(3.84±0.82)mmol/L、(1.74±0.56)mmol/L、(2.06±0.71)mmol/L、(1.24±0.52)mmol/L;C组治疗后TC、TG及LDL-C水平均显著优于A、B组,差异均有统计学意义(F=3.80、4.94、4.21,均P<0.05);但三组治疗后HDL-C水平差异无统计学意义(P>0.05);A、B及C组不良反应发生率分别为1.25%(1/80)、3.75%(3/80)、2.50%(2/80),三组不良反应发生率差异无统计学意义(χ2=1.03,P<0.05)。结论胆固醇吸收抑制剂与高剂量阿托伐他汀联用于血脂控制不佳老年冠心病患者可有效控制血脂水平,提高血脂达标率,且未增加不良反应发生风险。
目的:探討膽固醇吸收抑製劑與高劑量阿託伐他汀聯用于血脂控製不佳老年冠心病患者的臨床效果及安全性差異。方法選取血脂控製不佳老年冠心病患者共240例,以隨機抽樣方法分為三組,即A組(80例)、B組(80例)即C組(80例),分彆採用阿託伐他汀常規劑量,阿託伐他汀高劑量及阿託伐他汀高劑量+膽固醇吸收抑製依摺麥佈治療,比較三組總膽固醇(TC )、低密度脂蛋白膽固醇(LDL-C )達標率,治療前後血脂指標及不良反應髮生率等。結果 A、B 及 C 組 TC 達標率分彆為40.00%(32/80)、62.50%(50/80)、96.25%(77/80);A、B 及 C 組 LDL-C 達標率分彆為51.25%(41/80)、81.25%(65/80)、98.75%(79/80);C組TC和LDL-C達標率顯著優于A、B組,差異有統計學意義(χ2=58.28、27.83、48.13、13.61,均P<0.05);A組治療後TC、TG、LDL-C及HDL-C分彆為(5.35±1.26)mmol/L、(2.10±0.83)mmol/L、(2.85±0.93)mmol/L、(1.23±0.67)mmol/L;B 組治療後 TC、TG、LDL-C 及 HDL-C 分彆為(4.97±1.02)mmol/L,(2.05±0.81)mmol/L,(2.47±0.86)mmol/L,(1.20±0.65)mmol/L;C組治療後TC、TG、LDL-C及HDL-C分彆為(3.84±0.82)mmol/L、(1.74±0.56)mmol/L、(2.06±0.71)mmol/L、(1.24±0.52)mmol/L;C組治療後TC、TG及LDL-C水平均顯著優于A、B組,差異均有統計學意義(F=3.80、4.94、4.21,均P<0.05);但三組治療後HDL-C水平差異無統計學意義(P>0.05);A、B及C組不良反應髮生率分彆為1.25%(1/80)、3.75%(3/80)、2.50%(2/80),三組不良反應髮生率差異無統計學意義(χ2=1.03,P<0.05)。結論膽固醇吸收抑製劑與高劑量阿託伐他汀聯用于血脂控製不佳老年冠心病患者可有效控製血脂水平,提高血脂達標率,且未增加不良反應髮生風險。
목적:탐토담고순흡수억제제여고제량아탁벌타정련용우혈지공제불가노년관심병환자적림상효과급안전성차이。방법선취혈지공제불가노년관심병환자공240례,이수궤추양방법분위삼조,즉A조(80례)、B조(80례)즉C조(80례),분별채용아탁벌타정상규제량,아탁벌타정고제량급아탁벌타정고제량+담고순흡수억제의절맥포치료,비교삼조총담고순(TC )、저밀도지단백담고순(LDL-C )체표솔,치료전후혈지지표급불량반응발생솔등。결과 A、B 급 C 조 TC 체표솔분별위40.00%(32/80)、62.50%(50/80)、96.25%(77/80);A、B 급 C 조 LDL-C 체표솔분별위51.25%(41/80)、81.25%(65/80)、98.75%(79/80);C조TC화LDL-C체표솔현저우우A、B조,차이유통계학의의(χ2=58.28、27.83、48.13、13.61,균P<0.05);A조치료후TC、TG、LDL-C급HDL-C분별위(5.35±1.26)mmol/L、(2.10±0.83)mmol/L、(2.85±0.93)mmol/L、(1.23±0.67)mmol/L;B 조치료후 TC、TG、LDL-C 급 HDL-C 분별위(4.97±1.02)mmol/L,(2.05±0.81)mmol/L,(2.47±0.86)mmol/L,(1.20±0.65)mmol/L;C조치료후TC、TG、LDL-C급HDL-C분별위(3.84±0.82)mmol/L、(1.74±0.56)mmol/L、(2.06±0.71)mmol/L、(1.24±0.52)mmol/L;C조치료후TC、TG급LDL-C수평균현저우우A、B조,차이균유통계학의의(F=3.80、4.94、4.21,균P<0.05);단삼조치료후HDL-C수평차이무통계학의의(P>0.05);A、B급C조불량반응발생솔분별위1.25%(1/80)、3.75%(3/80)、2.50%(2/80),삼조불량반응발생솔차이무통계학의의(χ2=1.03,P<0.05)。결론담고순흡수억제제여고제량아탁벌타정련용우혈지공제불가노년관심병환자가유효공제혈지수평,제고혈지체표솔,차미증가불량반응발생풍험。
Objective To investigate clinical effects and safety difference of cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling. Methods 240 elderly patients with coronary heart disease and poor lipid controlling were chosen and randomly divided into 3 groups including group A (80 patients)with atorvastatin for conventional dose,group B (80 patients)with atorvastatin for high dose and group C (80 patients)with atorvastatin for high dose associated with ezetimibe for cholesterol absorption inhibitor;and the compliance rate of total cholesterol (TC)and low density lipoprotein cholesterol (LDL-C),serum lipids before and after treatment and the incidence of adverse reaction of 3 groups were compared. Results The compliance rate of TC of group A,group B and group C were separately 40.00%(32/80),62.50%(50/80)and 96.25%(77/80);the compliance rate of LDL-C of group A,group B and group C were separately 51.25%(41/80),81.25%(65/80)and 98.75%(79/80);the compliance rate of TC and LDL-C of group C was significant better than that of group A and group B (χ2 =58.28,27.83,48.13,13.61,all P<0.05).The levels of TC,TG,LDL-C and HDL-C of group A after treatment were separately (5.35 ±1.26)mmol/L,(2.10 ±0.83) mmol/L,(2.85 ±0.93)mmol/L and (1.23 ±0.67)mmol/L;the levels of TC,TG,LDL-C and HDL-C of group B after treatment were separately (4.97 ±1.02)mmol/L,(2.05 ±0.81)mmol/L,(2.47 ±0.86)mmol/L and (1.20 ± 0.65)mmol/L;the levels of TC,TG,LDL -C and HDL -C of C group after treatment were separately (3.84 ± 0.82)mmol/L,(1.74 ±0.56)mmol/L,(2.06 ±0.71)mmol/L and (1.24 ±0.52)mmol/L.The levels of TC,TG and LDL-C of group C after treatment was significant better than group A and group B (F=3.80,4.94,4.21,all P<0.05).There was no significant difference in level of HDL-C among 3 groups after treatment(P>0.05).The incidences of adverse reaction of group A,group B and group C were separately 1.25%(1/80),3.75%(3/80)and 2.50%(2/80);there was no significant difference in incidence of adverse reaction among 3 groups(χ2 =1.03,P>0.05).Conclusion Cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling can efficiently control blood lipid levels,improve compliance rate of blood lipids,and did not increase the risk of adverse reaction.